The MIPSS70 and MIPSS70-plus were developed based on the publication:
MIPSS70: Mutation Enhanced International Prognostic Score System for Transplant Age Patients with Primary Myelofibrosis
by P. Guglielmelli et al., Journal of Clinical Oncology, 2017.
The MIPSS70 and MIPSS70-plus score are applicable to patients with primary myelofibrosis of transplant-age (<70 years), and integrate prognostically-relevant clinical, cytogenetic and mutation information. The interpretation of the results of the score is of exclusive pertinence of expert physicians and does not represent, under any respect, guideline for clinical-decision making.
The web application was developed by Lorenzo Piccinini.